Abstract: With the increasing number of transgender and gender diverse (TGD) individuals who are seeking gender-affirming care, there is a clear need for the development and collection of evidence-based data to establish guidelines for patient care. TGD individuals are estimated to represent 0.3 to 4.5% of the world population. Gender-affirming care that includes hormone therapy helps to align the body of a transgender person with their gender identity. Hormone therapy requires monitoring for both safety and efficacy. The extent to which gender-affirming hormone therapy alters cancer risk remains unknown. Because of a lack of comprehensive data collection pertaining to this patient population, endocrine cancer data including incidence and outcomes is limited. Dedicated research is needed to help address the gap in knowledge pertaining to the risk of cancer in the TGD population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1530/ERC-23-0214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chiropractic Care for a Posterior Tibialis Tendon Tear in a Transgender Male Athlete with Gender-Affirming Hormone Therapy.
J Chiropr Med
December 2024
Logan University, Chesterfield, Missouri.
Objective: The purpose of this case study was to report the management of a patient with posterior tibialis tendon injury concurrent with gender-affirming hormone therapy (GAHT).
Clinical Features: A 31-year-old transgender male presented to a chiropractic clinic with spontaneous, right medial foot pain following running that day. Medical history revealed bilateral congenital pes planus and intramuscular administration of testosterone for 8 years.
Gender-Affirming Voice Therapy Duration and Satisfaction: Experiences from a Single Institution.
J Voice
January 2025
UCSF Voice and Swallowing Center, Department of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, California. Electronic address:
Objective: Current literature involving gender-affirming voice therapy (GAVT) for transgender and nonbinary (TGNB) individuals is limited. This study describes treatment duration and satisfaction at a single institution.
Study Design: Retrospective cohort.
Gender-Affirming Medications Among Transgender Adolescents in the US, 2018-2022.
JAMA Pediatr
January 2025
FOLX Health, Boston, Massachusetts.
AusPATH: Activism influencing health policy.
Australas Psychiatry
January 2025
Senior Clinical Lecturer, Faculty of Health and Medical Science, University of Adelaide, Adelaide, SA, Australia.
Objective: To consider the role of AusPATH and its position statements on health policy in Australia.
Conclusions: As a consequence of a membership policy which admits members with lived experience as health experts, AusPATH functions as an activist organisation whilst claiming to be a professional association. There is no accreditation or endorsement underpinning AusPATH's influence on health policy in Australia.
Providers' Beliefs and Values: Understanding Their Approach to Gender-Affirming Care.
J Prim Care Community Health
January 2025
University of Rochester, Rochester, NY, USA.
Objectives: This qualitative study explored the beliefs and values influencing healthcare providers' delivery of gender-affirming care (GAC) to transgender and gender-diverse (TGD) youth amidst current social and political dynamics.
Methods: The study PI conducted 43 semi-structured interviews with providers across states with varying GAC legislation. Responses from 41 providers were analyzed in this paper.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!